This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Viemed Healthcare, Inc. (VMD) Misses Q1 Earnings Estimates
by Zacks Equity Research
Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -42.86% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
by Zacks Equity Research
Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.
BellRing Brands Inc. (BRBR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 8% and 7.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viemed Healthcare, Inc. (VMD) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Viemed Healthcare, Inc. (VMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Elevance Health (ELV) Beats on Q1 Earnings, Hikes Profit View
by Zacks Equity Research
Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.
UnitedHealth (UNH) Beats on Q1 Earnings, Ups EPS 2023 View
by Zacks Equity Research
Strong membership growth and consistent management of medical and operating costs aid UnitedHealth's (UNH) UnitedHealthcare unit in the first quarter.
Viemed Healthcare, Inc. (VMD) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Viemed Healthcare, Inc. (VMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Brookdale (BKD) Q1 Adjusted EBITDA to Beat View, Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 17 straight months of year-over-year increases in weighted average occupancy level.
Palo Alto Networks and RH have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Palo Alto Networks and RH are part of the Zacks Bull and Bear of the Day article.
3 Medical Product Stocks With Strong Potential to Gain in 2023
by Indrajit Bandyopadhyay
Here we discuss three medical instruments stocks, LNTH, RMTI and VMD, which are witnessing solid momentum in 2023. These stocks have the potential to continue their uptrend going forward.
Boston Scientific (BSX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.
UnitedHealth (UNH) Arm to Reduce Prior Authorization Time
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.
Tenet Healthcare (THC) Jumps 14.9% YTD: More Growth Ahead?
by Zacks Equity Research
Tenet Healthcare's (THC) focus on boosting USPI's network is positioning the company for expedited growth.
Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia
by Zacks Equity Research
The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.
3 Medical Device Stocks With Potential to Fight Recession Risk
by Indrajit Bandyopadhyay
Increasing interest rates, higher costs and rising unemployment paint an unfavorable picture with the risk of a recession looming large. Here we discuss three medical stocks that may be good bets even in a recession.
Recent Price Trend in Viemed Healthcare, Inc. (VMD) is Your Friend, Here's Why
by Zacks Equity Research
Viemed Healthcare, Inc. (VMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal
by Zacks Equity Research
The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.
Humana (HUM) Rises 9.7% in a Year: More Room for Growth?
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.
Encompass Health's (EHC) 155th Hospital Opens in Wisconsin
by Zacks Equity Research
The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.
UnitedHealth (UNH) Plan in Indiana to Offer Pathways Program
by Zacks Equity Research
UnitedHealth (UNH) expects the new Pathways for Aging program to serve around 100,000 people.
Brookdale Senior (BKD) February Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 16 straight months of year-over-year increases in weighted average occupancy level.
Viemed Healthcare, Inc. (VMD) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Viemed Healthcare, Inc. (VMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Viemed Healthcare, Inc. (VMD) Lags Q1 Earnings Estimates
by Zacks Equity Research
Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -33.33% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?